Psychedelic research in April pitted psychedelics against SSRIs, gave mice a break from tripping, and identified new psychedelics. As we’re awaiting the full results of the MAPS Phase III MDMA trial data, let’s look back at key research published last month. This month’s most important and most debated study investigated psilocybin (2 high doses) and Escitalopram (six weeks)…


Previous articlePsychedelic Bulletin: MDMA Sees Success at Phase 3; MindMed Targets Pain; the Proliferation of Deuteration
Next articleTryp Therapeutics Partners with Clinlogix for Clinical Trial Support